Jasper Therapeutics, Inc. (JSPR)
After hours:
| Previous close | 21.26 |
| Open | 21.29 |
| Bid | 20.47 x 200 |
| Ask | 20.66 x 100 |
| Day's range | 20.33 - 21.64 |
| 52-week range | 4.00 - 31.01 |
| Volume | |
| Avg. volume | 147,183 |
| Market cap | 310.613M |
| Beta (5Y monthly) | 2.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -61.21 |
| Earnings date | 09 Aug 2024 - 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 73.00 |
GlobeNewswireJasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper’s Board of Directors (the Board), effective as of June 18, 2024. Sep
- GlobeNewswire
Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit
REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced today announced that its management will present at the Oppenheimer Novel Targets in Immunology Summit, to be held on Monday, June 24,
- GlobeNewswire
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today is presenting preclinical data demonstrating the effect of briquilimab on hematopoietic stem cells (HSCs) at the European Hematolo
